Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Return on Equity (2020 - 2025)

Maxcyte (MXCT) has disclosed Return on Equity for 5 consecutive years, with 0.25% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 8.0% to 0.25% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.25%, a 8.0% decrease, with the full-year FY2024 number at 0.19%, down 3.0% from a year prior.
  • Return on Equity was 0.25% for Q3 2025 at Maxcyte, down from 0.23% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.06% in Q1 2022 to a low of 0.25% in Q3 2025.
  • A 5-year average of 0.15% and a median of 0.16% in 2024 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: grew 17bps in 2022, then decreased -8bps in 2025.
  • Maxcyte's Return on Equity stood at 0.07% in 2021, then decreased by -28bps to 0.09% in 2022, then crashed by -76bps to 0.16% in 2023, then decreased by -20bps to 0.2% in 2024, then decreased by -26bps to 0.25% in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Return on Equity are 0.25% (Q3 2025), 0.23% (Q2 2025), and 0.21% (Q1 2025).